Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509197 | 0.84 | KCNH2 (0.37) | KCNH2PTGDR2MAPT | |
| SCHEMBL6626065 | 0.84 | PDE4B (0.35) | ADCY10PDE4BKCNH2PTGDR2KLKB1 | |
| SCHEMBL509399 | 0.84 | MAPT (0.36) | PDE4BPTGDR2KLKB1MAPT | |
| SCHEMBL509118 | 0.81 | MAPT (0.35) | KCNH2PTGDR2MAPT | |
| SCHEMBL5233666 | 0.81 | PTGDR2 (0.33) | PTGDR2KLKB1MAPT | |
| SCHEMBL10285156 | 0.80 | DRD2 (0.34) | PTGDR2KLKB1MAPT | |
| SCHEMBL509474 | 0.79 | MAPT (0.34) | KCNH2PTGDR2MAPT | |
| SCHEMBL12132021 | 0.75 | FAAH (0.35) | KCNH2PTGDR2MAPT | |
| SCHEMBL508284 | 0.75 | LMNA (0.36) | PTGDR2MAPT | |
| SCHEMBL509302 | 0.75 | PTGDR2 (0.38) | KCNH2PTGDR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | ADCY10 4847/4885PDE4B 3638/4885KCNH2 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.